Market Minds Advisory
Autoimmune Disease Testing Market

Autoimmune Disease Testing Market: Multiplex Panel and Biomarker-Driven Diagnostics Dynamics

Multiplex assay platforms are replacing sequential single-analyte autoantibody testing faster than smaller reference laboratories can afford to retool, concentrating volume among manufacturers who can prove equivalent accuracy across many biomarkers at once.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$5.4BMarket Size 2025
2036 FORECAST VALUE$13.1BBase Case , 2026 to 2036
CAGR 2026 TO 20368.4 %Bull 9.6% / Bear 7.1%
INCREMENTAL OPPORTUNITY$7.3BNet 10- year value creation
EXPANSION MULTIPLE2.24x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Autoimmune disease testing is shifting from sequential single-analyte antibody testing toward multiplex panel technology as laboratories seek faster turnaround and lower per-analyte cost without sacrificing the diagnostic accuracy rheumatologists depend on for treatment decisions. That shift is reshaping which manufacturers laboratories trust most. today. Investors are tracking this shift closely.
Novel biomarker and companion diagnostic testing forms the fastest-growing segment as new biologic therapies increasingly require biomarker-confirmed patient eligibility before treatment initiation rather than symptom-based diagnosis alone. Western Europe anchors the deepest commercial concentration, reflecting Germany's dominant position in multiplex autoimmune diagnostic technology and concentrated European in vitro diagnostics manufacturing base that developing regions still cannot fully replicate at comparable technical scale today.
Roche Diagnostics and Siemens Healthineers set the technology benchmark through broad integrated testing platform breadth and deep multiplex assay automation expertise respectively, while a fragmented tier of specialized diagnostics developers competes on narrow biomarker panel depth. Expanding multiplex panel adoption and tightening biomarker-driven treatment eligibility requirements are both reshaping which companies capture testing volume as validated panel accuracy increasingly outweighs single-analyte legacy testing across the category. Smaller developers form technology partnerships to remain competitive.
Market Definition
The autoimmune disease testing market covers in vitro diagnostic assays used to detect autoantibodies and biomarkers associated with autoimmune conditions including rheumatoid arthritis, lupus, celiac disease, and autoimmune thyroid disease. It spans single-analyte enzyme-linked immunosorbent assays, multiplex panel platforms, and companion diagnostic tests sold to hospital laboratories, reference laboratories, and physician office testing settings. Autoimmune disease treatment products, unrelated infectious disease serology testing, and general inflammatory marker panels without autoimmune-specific indication are excluded from this scope.
Base Year Value
$5.4B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.4% base case. Bull 9.6%. Bear 7.1%.
Fastest Growth Segment
Novel Biomarker and Companion Diagnostic Testing: 14.8% CAGR
Fastest Growth Country
Mexico: 11.2% CAGR
Fastest Growth Region
South Asia and Pacific: 10.4% CAGR
Largest Region
Western Europe: 27% of 2025 global value
Market Leaders
Roche Diagnostics, Siemens Healthineers, Revvity, Bio-Rad Laboratories, Werfen. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Autoimmune Disease Testing Market Forecast Scenarios

autoimmune-disease-testing-market-size-forecast-scenario-1787305916061
Autoimmune disease testing demand grew steadily across 2020 to 2025 as rising diagnosed autoimmune disease prevalence expanded testing volume, then accelerated further as multiplex panel technology matured enough to displace sequential single-analyte testing workflows. The market grew at an estimated 7.2% historical CAGR across the period, reflecting steady diagnostic volume growth that stepped up meaningfully once multiplex efficiency gains became commercially proven.
The base case assumes multiplex panel adoption continues broadening across major developed laboratory markets through 2030, biomarker-driven companion diagnostic requirements keep expanding as new biologic therapies reach approval, and diagnosed autoimmune disease prevalence keeps rising across both developed and emerging markets. Together these three mechanisms support an 8.4% forecast CAGR, with single-analyte ANA testing remaining the volume anchor even as multiplex and companion diagnostic formats capture growing value share each year worldwide.
The bull case centers on faster-than-expected multiplex panel adoption that pushes laboratory conversion well ahead of current reference laboratory capital investment timelines. The bear case centers on renewed reimbursement scrutiny following cost-effectiveness disputes over expanded panel testing, which would slow laboratory adoption and compress developer valuations across cost-constrained health systems for several years as consolidation accelerates.

Multiplex Efficiency and Biomarker Confirmation Dynamics

Autoimmune disease testing sits at the intersection of immunoassay engineering and rheumatology clinical practice, since a multiplex panel must satisfy both rigorous cross-reactivity validation across dozens of simultaneous biomarkers and the clinical accuracy that rheumatologists depend on when making treatment decisions. That split has kept the vendor base divided between large diversified diagnostics companies and specialized immunoassay developers competing on multiplex validation depth.
TOP 5 CONCENTRATION44%share held by leading five autoimmune disease testing companies
AVERAGE PANEL TEST PRICE$185 per multiplex paneltypical price across a standard multiplex autoantibody panel
LEADING COUNTRY SHAREGermany, 14%share of global autoimmune disease testing commercial revenue
MULTIPLEX ADOPTION RATE38% of reference laboratoriesshare of reference laboratories running multiplex panel platforms
COMPANION DIAGNOSTIC REQUIREMENT RATE22% of new biologic launchesshare of new biologic launches requiring biomarker confirmation testing
TURNAROUND TIME REDUCTION48% versus sequential testingtypical turnaround improvement relative to sequential single-analyte testing
Commercially, the market splits between a mature single-analyte ANA and rheumatoid factor base sold through established hospital and reference laboratory relationships built over decades of clinical adoption, and a smaller but faster-growing multiplex and companion diagnostic tier sold on turnaround efficiency and biomarker confirmation rather than price alone. Celiac and thyroid panels round out demand with purchasing tied to screening protocol requirements.
Over the next decade, multiplex validation depth and companion diagnostic regulatory approval will matter more than raw testing menu breadth alone, since laboratories increasingly select platform partners based on demonstrated cross-reactivity accuracy rather than which supplier offers the broadest single-analyte catalog. Companies that expand multiplex evidence into mid-tier reference laboratory relationships fastest stand to capture a widening share of a market that biomarker-driven treatment eligibility is reshaping as much as diagnosis volume growth is.
"Running forty separate tubes through forty separate assays used to be normal. Now a rheumatologist expects one panel, one report, and an answer before the patient leaves the building, and that expectation is what's actually driving capital spending in this category."
Director, Immunology Diagnostics and Laboratory Medicine Practice · MMA Healthca

Market Trends

Multiplex Panels Replace Sequential Single-Analyte Testing

Reference laboratories are increasingly replacing sequential single-analyte autoantibody testing with multiplex panel platforms that measure dozens of biomarkers simultaneously from a single patient sample, reducing turnaround time and per-analyte cost relative to running each test separately. Siemens Healthineers and Revvity have both expanded multiplex panel validation investment since 2023, targeting laboratories that want faster comprehensive results without compromising individual analyte accuracy. Smaller reference laboratories are adopting this technology more slowly, constrained by the capital investment required for platform conversion, but adoption is broadening steadily each year across major diagnostic markets worldwide.
Market Impact: Adds 5% annual diagnosed patient gr

Biologic Therapy Approvals Drive Companion Diagnostic Demand

New biologic therapies for autoimmune conditions increasingly require biomarker-confirmed patient eligibility testing before treatment initiation, creating dedicated companion diagnostic demand that did not exist for earlier generations of symptom-based autoimmune treatment protocols. Roche Diagnostics and Bio-Rad Laboratories have both expanded companion diagnostic development investment since 2023, targeting pharmaceutical partners that need validated biomarker tests to support new drug approval submissions. This companion diagnostic trend is broadening steadily each year across major biologic development pipelines worldwide. Health systems increasingly view companion diagnostic partnerships as a critical pipeline investment priority worth pursuing.
Market Impact: Adds 7% annual companion testing gr

Market Opportunities and Growth Drivers

Rising Autoimmune Disease Diagnosis Sustains Volume Growth

Global autoimmune disease diagnosis rates continue rising each year as improved clinical awareness and expanding diagnostic access identify cases that previously went undiagnosed or misattributed to other conditions, sustaining long-term demand for autoimmune testing regardless of near-term laboratory budget cycles in any single market. This diagnosis growth provides a durable baseline volume floor beneath the faster-growing multiplex adoption trend layered on top of it, since underlying autoimmune disease prevalence continues expanding independent of specific testing technology choices. Health systems increasingly prioritize earlier autoimmune diagnosis as a standard rheumatology care component.
Market Impact: Delays platform conversion by 16 mo

Expanding Biologic Pipeline Sustains Companion Testing Demand

The autoimmune biologic therapy development pipeline continues expanding each year as pharmaceutical companies pursue increasingly targeted treatment mechanisms requiring biomarker-confirmed patient selection, sustaining long-term companion diagnostic demand regardless of near-term reimbursement cycles in any single market. This pipeline growth provides a durable baseline demand floor beneath the faster-growing multiplex panel trend layered on top of it, since underlying companion diagnostic requirements continue expanding independent of multiplex technology adoption specifically. Diagnostics companies increasingly prioritize companion diagnostic partnerships as a strategic pipeline investment. Companies with strong pharmaceutical relationships increasingly capture this expanding demand ahead of less-prepared competitors.
Market Impact: Delays approval by 20 months

Market Restraints and Challenges

Multiplex Platform Conversion Requires Substantial Capital Investment

Converting a reference laboratory from sequential single-analyte testing infrastructure to multiplex panel platforms requires substantial capital investment in specialized instrumentation and staff retraining that many smaller regional laboratories cannot readily justify given their existing single-analyte production scale. This constraint is particularly burdensome for laboratories serving lower-volume regional markets where multiplex platform utilization economics remain difficult to achieve relative to large reference laboratory networks. Companies are responding by pursuing flexible leasing arrangements and shared platform partnerships that reduce the upfront capital barrier for smaller laboratory operators across most affected regions today.
Market Impact: Cuts turnaround time by 48%

Cross-Reactivity Validation Complexity Slows New Panel Approval

Validating a new multiplex panel requires extensive cross-reactivity testing to confirm that measuring dozens of biomarkers simultaneously does not compromise individual analyte accuracy, creating a lengthy validation pathway that takes considerably longer than validating conventional single-analyte assays alone. This requirement is particularly burdensome for smaller diagnostics developers lacking the analytical infrastructure and regulatory relationships that larger established companies maintain internally for faster validation turnaround. Companies are responding by investing in expanded validation capability and pursuing platform-based approaches that can support multiple panel configurations simultaneously across the broader industry today. today.
Market Impact: Adds $95 per companion diagnostic t
3 additional market trends, 3 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Autoimmune disease tests segment by biomarker and platform type, the classification laboratories and payers use to set reimbursement pathway, validation requirements, and pricing tier, since single-analyte, multiplex, and companion diagnostic buyers each negotiate under distinct clinical terms. Vendors price each category differently depending on panel complexity and biomarker specificity involved. across the broader industry.
autoimmune-disease-testing-market-market-share-analysis-1787305916598

Novel Biomarker and Companion Diagnostic Testing

Novel biomarker and companion diagnostic testing forms the fastest-growing segment as new biologic therapies increasingly require biomarker-confirmed patient eligibility before treatment initiation rather than symptom-based diagnosis alone. Roche Diagnostics and Bio-Rad Laboratories have both expanded companion diagnostic development investment since 2023, targeting pharmaceutical partners that need validated biomarker tests to support new drug approval submissions. Companies that secure early pharmaceutical partnerships are capturing testing volume from competitors that lack comparable companion diagnostic development capability, an advantage that compounds as more biologic developers standardize around a smaller set of trusted diagnostic partners. If biologic pipeline expansion continues at the current pace, this segment could approach a meaningful share of total category value within the next several years.
CAGR 14.8%

Multiplex Autoantibody Panel Testing

Multiplex autoantibody panel testing forms the second-fastest segment as reference laboratories increasingly adopt platforms that measure dozens of biomarkers simultaneously from a single patient sample, reducing turnaround time relative to sequential single-analyte testing workflows. Siemens Healthineers and Revvity have both expanded multiplex panel validation capability since 2023, targeting laboratories that want faster comprehensive results without compromising individual analyte accuracy. Laboratories that adopt multiplex platforms early are capturing testing volume from competitors lacking comparable panel breadth and turnaround efficiency, an advantage that compounds as more rheumatologists standardize around comprehensive single-draw panel ordering across their broader patient populations. Payers increasingly view this segment as a durable long-term differentiator worth monitoring closely. That trajectory should strengthen as more laboratories adopt validated panel protocols.
CAGR 12.2%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Autoimmune disease testing commercial activity concentrates where multiplex diagnostic technology and in vitro diagnostics manufacturing infrastructure are most developed, even though underlying diagnosed patient population runs globally distributed rather than concentrated in any particular region each year. particularly across major technology and manufacturing infrastructure markets tracked globally.

North America

The United States accounts for the overwhelming majority of North America's autoimmune disease testing commercial value, reflecting dense reference laboratory infrastructure and comprehensive private payer reimbursement supporting broad multiplex panel adoption across major hospital and reference laboratory networks. Canada contributes a smaller but meaningful share through its established provincial laboratory testing infrastructure. Multiplex adoption runs meaningfully ahead of the global average across most large reference laboratory networks in the region. Companion diagnostic partnership activity continues concentrating steadily each year across major biotechnology hubs nationwide. Laboratory purchasing committees increasingly consolidate vendor relationships with fewer, larger-scale manufacturers to secure reliable panel supply and pricing continuity. That consolidation trend continues strengthening steadily each year across the sector.
Share: 26% | CAGR: 7.8% (2026 to 2036)

Western Europe

Germany anchors Western Europe's autoimmune disease testing commercial value through Euroimmun's dominant position in multiplex autoimmune diagnostic technology and the country's concentrated in vitro diagnostics manufacturing base, a combination that pushes the region above its default commercial share band, reflecting a genuine technology and manufacturing concentration rather than a default geographic assumption. France and the United Kingdom contribute smaller but meaningfully growing shares through their established national health system laboratory infrastructure. Regional multiplex panel innovation continues setting the global technology benchmark each year across the broader diagnostics industry. Regional laboratories increasingly benchmark validation protocols against Euroimmun's established precedent each year across the broader diagnostics sector. That benchmarking trend continues strengthening regional credibility steadily each year.
Share: 27% | CAGR: 6.9% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
autoimmune-disease-testing-market-country-cagr-analysis-1787305917113

Where Diagnostic Value Concentrates Next

Revenue growth in autoimmune disease testing increasingly depends on capturing multiplex panel conversion, companion diagnostic partnership development, and biomarker validation depth rather than raw single-analyte volume alone, since diagnostic efficiency evidence, not raw testing menu breadth, is reshaping where value concentrates across the industry today. The levers below outline where that value is concentrating fastest across the industry today.

Expanding Multiplex Panel Validation Capability Further

Companies expanding multiplex panel validation capability are capturing laboratory relationships that single-analyte-only competitors cannot fulfill, particularly as more laboratories face growing pressure to reduce turnaround time and per-analyte cost. Building competitive multiplex validation capability typically costs $20 million to $45 million in cross-reactivity testing, clinical validation, and regulatory submission investment. Companies without adequate validation investment increasingly lose laboratory relationships to better-evidenced competitors offering proven multiplex accuracy sooner. Adoption continues broadening steadily as more laboratories seek comprehensive panel efficiency. Adoption continues broadening steadily as more laboratories seek comprehensive panel efficiency gains.
Market Impact: Costs $20 to $45 million to fully b

Building Companion Diagnostic Pharmaceutical Partnerships Now

Companies building dedicated companion diagnostic partnerships with pharmaceutical developers are capturing testing volume that standalone diagnostic-only competitors cannot access for biologic therapies requiring biomarker-confirmed eligibility. Developing competitive companion diagnostic capability typically costs $28 million to $60 million in regulatory co-development, clinical validation, and manufacturing coordination investment. Companies with superior companion diagnostic capability increasingly win pharmaceutical partnership relationships from competitors offering only standalone diagnostic alternatives. Adoption continues broadening steadily. Adoption continues broadening steadily as more developers seek coordinated diagnostic partnerships worldwide. That advantage compounds each successive year. Developers increasingly favor companies demonstrating consistent investment.
Market Impact: Costs $28 to $60 million to fully b

Securing Large Reference Laboratory Network Contracts

Companies securing dedicated contracts with large reference laboratory networks are capturing volume growth that transactional individual hospital laboratory relationships cannot match on scale and long-term testing menu commitment. These partnerships typically carry a 14 to 22% margin premium given the coordinated menu integration and volume predictability large networks provide. Companies able to demonstrate reliable multiplex accuracy increasingly win these contracts over less-prepared competitors seeking similar network access. Adoption continues broadening steadily. Adoption continues broadening steadily as more networks seek coordinated testing menu relationships. That advantage compounds each successive year. today.
Market Impact: Commands a 14 to 22% margin premium

Investing In Rare Biomarker Panel Expansion Capability

Companies investing in rare biomarker panel expansion capability are positioned to capture testing volume from patients with less common autoimmune presentations that standard panel offerings cannot fully address for laboratories seeking maximum diagnostic comprehensiveness. Developing competitive rare biomarker capability typically costs $10 million to $24 million in assay development, clinical validation, and reagent sourcing investment. Companies with strong rare biomarker capability increasingly win specialty laboratory relationships from competitors offering only standard panel alternatives. Adoption continues broadening steadily as more laboratories seek maximum diagnostic comprehensiveness. That advantage compounds each successive year across the category.
Market Impact: Costs $10 to $24 million to fully b

Who Controls the Margin Pool

The top five vendors hold an estimated 44% of global autoimmune disease testing revenue, a moderate concentration reflecting the category's mix of large diversified diagnostics companies and specialized immunoassay developers still building toward broader multiplex commercial scale. Roche Diagnostics and Siemens Healthineers lead on platform breadth and multiplex automation expertise respectively, while a fragmented tier of specialized developers competes on narrow biomarker panel depth.
Current competitive activity centers on three fronts. Multiplex panel validation expansion is opening a new front for companies willing to invest ahead of confirmed broader laboratory conversion. Companion diagnostic partnership development is becoming increasingly important as companies compete for pharmaceutical relationships beyond standalone testing sales. And several mid-sized developers are pursuing large reference laboratory network contracts to differentiate beyond commoditized individual hospital sales.

Emerging pressure comes from specialized immunoassay developers advancing rare biomarker and companion diagnostic candidates as they partner with academic medical centers and pharmaceutical companies, though matching Roche Diagnostics or Siemens Healthineers's platform breadth and automation expertise remains years away for most. If these challengers close that gap, expect share to shift within specific biomarker categories first, before pressure reaches the largest diversified incumbents.
autoimmune-disease-testing-market-company-positioning-matrix-1787305917626

Competitive Moat and Risk Dimensions

F. HOFFMANN-LA ROCHE LTD.

Moat: Broad Integrated Autoimmune Testing Platform

Roche Diagnostics maintains one of the industry's broadest integrated autoimmune testing platforms spanning single-analyte, multiplex, and companion diagnostic offerings, giving it comprehensive menu breadth that narrower competitors cannot match across every major laboratory relationship. That platform breadth lets Roche Diagnostics capture testing volume regardless of which specific technology a given laboratory prefers.
F. HOFFMANN-LA ROCHE LTD.

Risk: High Capital Intensity Limits Flexibility

Roche Diagnostics' broad platform portfolio requires substantial ongoing capital investment in specialized immunoassay and multiplex equipment that constrains flexibility relative to competitors with lower fixed-asset intensity in adjacent diagnostic categories. If category growth accelerates faster than Roche Diagnostics' capacity expansion allows, it risks ceding emerging laboratory relationships to more agile smaller competitors.
SIEMENS HEALTHINEERS AG

Moat: Deep Multiplex Assay Automation Expertise

Siemens Healthineers maintains deep multiplex assay automation expertise built through years of continuous investment in laboratory instrumentation engineering that gives it a technical credibility advantage among laboratories evaluating platform conversion decisions. That automation depth lets Siemens Healthineers offer superior turnaround efficiency that less automated competitors cannot easily match.
SIEMENS HEALTHINEERS AG

Risk: Complex Multi-Analyte Manufacturing Coordination

Siemens Healthineers' broad multiplex portfolio spanning dozens of simultaneous biomarkers creates meaningful manufacturing coordination complexity relative to competitors with more focused single-analyte production operations. If manufacturing complexity creates supply disruption across any major panel configuration, Siemens Healthineers risks broader reputational and commercial impact than more narrowly focused competitors would face.

Players Tracked

Prominent Players

F. Hoffmann-La Roche Ltd.
Siemens Healthineers AG
Revvity Inc.
Bio-Rad Laboratories Inc.
Werfen S.A.

Other Key Players

Abbott Laboratories
Thermo Fisher Scientific Inc.
Grifols S.A.
Beckman Coulter Inc.
Trinity Biotech plc
QuidelOrtho Corporation
Immunodiagnostic Systems Holdings PLC
ELITechGroup SAS
Aesku.Diagnostics GmbH and Co. KG
MedMira Inc.
Svar Life Science AB
Alpha Laboratories Ltd.
R-Biopharm AG
Zeus Scientific Inc.
Diasorin S.p.A.

Recent Developments

APRIL 2025

Siemens Healthineers Expands Multiplex Panel Validation Program

Siemens Healthineers expanded its multiplex autoantibody panel validation program to add additional biomarkers, following extensive cross-reactivity testing across multiple reference laboratory sites demonstrating comparable accuracy to sequential single-analyte testing. Similar validation programs are expected across other qualified competitors soon industry-wide. Payers cited the validation when reviewing broader coverage decisions.
Signal: Confirms multiplex panel breadth remains t
OCTOBER 2024

Roche Diagnostics Signs Multi-Year Reference Laboratory Agreement

Roche Diagnostics secured a multi-year testing menu agreement with a major reference laboratory network, guaranteeing multiplex panel and companion diagnostic access through 2029 across several affiliated laboratory sites. The agreement reflects laboratories' push to lock in reliable comprehensive testing menu partnerships ahead of expanding demand.
Signal: Shows laboratories prioritizing long-term
JANUARY 2025

Bio-Rad Laboratories Announces Companion Diagnostic Partnership

Bio-Rad Laboratories announced a new companion diagnostic development partnership with a major biologic therapy developer, guaranteeing biomarker confirmation testing support for an upcoming autoimmune treatment approval submission. Similar partnerships are expected across other qualified competitors over the coming year as demand grows. Analysts expect similar partnerships to follow soon.
Signal: Signals companion diagnostic partnerships

Reagent and Multiplex Validation Cost Pressure

Specialized immunoassay reagents and multiplex validation infrastructure together account for roughly 39% of effective cost of goods for autoimmune disease testing companies, given the specialized antibody sourcing and extensive cross-reactivity testing required for reliable multiplex panel performance at clinical scale. Regulatory submission and quality control costs add a further meaningful share, particularly for companies developing companion diagnostic products.
Immunoassay reagent and validation costs rose meaningfully following 2022 global specialty chemical and antibody supply disruption, with several companies reporting input cost increases exceeding 18% in their annual reports before pricing stabilized through 2023 and into 2024. Industry supply chain reviews have flagged specialized antibody reagent availability as this market's single most concentrated cost driver, more than validation or regulatory costs combined. Several companies have flagged reagent supply volatility as an ongoing operational risk.

Smaller specialty developers without long-term reagent supply agreements absorbed the 2022 cost increases hardest, losing laboratory contract bids to larger competitors including Roche Diagnostics and Siemens Healthineers that had negotiated priority supplier allocation years in advance. Companies with secured reagent supply weathered the cost increases far better than those dependent on spot market purchasing, a cost advantage that persists most sharply across smaller specialty developers today.
autoimmune-disease-testing-market-cost-volatility-analysis-1787305917822

Long-Term Reagent Supplier Agreements Secure Pricing

Companies increasingly negotiate multi-year specialized antibody reagent supply agreements with priority allocation clauses, reducing exposure to spot market price volatility during periods of broader specialty chemical supply disruption. This approach has helped several companies maintain more stable panel pricing during periods of input cost inflation. Several suppliers now offer flexible volume tiers for smaller manufacturers.

Shared Validation Infrastructure Lowers Fixed Cost

Smaller specialty developers increasingly share cross-reactivity validation infrastructure through partnership arrangements, spreading fixed testing cost across broader panel development volume than any single smaller operation could support alone economically. This shared infrastructure model has helped smaller developers remain competitive against larger integrated companies. This model has become increasingly common as smaller developers scale operations.

Vertical Integration Into Antibody Production Reduces Exposure

Several larger companies are investing in direct antibody production capability to reduce dependence on third-party reagent suppliers, gaining pricing control and supply security that non-integrated competitors cannot match during periods of tightening capacity. This integration also reduces exposure to spot market volatility. This structure increasingly appeals to companies seeking supply security today. today. across the sector.

Portfolio Architecture for Margin Defence

Autoimmune disease testing portfolios span three margin tiers, from commodity-adjacent standard single-analyte assays sold largely on price, through certified multiplex panels carrying efficiency-driven premiums, toward an emerging next-generation tier built around companion diagnostics and rare biomarker panels still gaining share. Gross margin widens meaningfully at each tier as panel complexity and validation depth increase across the industry today, reflecting growing willingness to pay for
The volume versus premium tension centers on validation and partnership investment allocation. Companies must choose between dedicating capital to high-margin multiplex and companion diagnostic programs with growing but still-smaller volume, or serving reliable single-analyte demand that fills out most testing volume across a typical year. Companies without spare capital increasingly favor higher-margin next-generation programs where competition remains comparatively thin still.

High-value margin pools concentrate in multiplex panels and companion diagnostics with completed validation, where reagent investment and evidence depth keep competition thin and laboratories pay a premium for proven comprehensive accuracy. Standard single-analyte assays remain the volume anchor but carry thinner margins across the portfolio, leaving smaller companies with fewer diversification options than larger integrated competitors today.

Volume / Commodity-Adjacent Tier

Standard single-analyte ANA and rheumatoid factor assays sold largely on price and laboratory purchasing relationships without efficiency-driven premiums, across most standard buyer segments worldwide. Pricing pressure from laboratory purchasing committees keeps margins comparatively thin across this tier.
Gross Margin: 20-30%

Premium / Certified Tier

Multiplex autoantibody panels sold under laboratory contracts carrying efficiency-driven pricing power built through years of proven turnaround and accuracy performance. Laboratories increasingly compare panel validation data before committing to a long-term relationship.
Gross Margin: 36-48%

Sustainability / Regulatory / Next-Generation Tier

Companion diagnostics and rare biomarker panels in active premium adoption, commanding premium pricing against limited proven alternatives as clinical evidence and regulatory approval expand across major markets. Companies with the deepest evidence and regulatory capability capture most of this premium value today.
Gross Margin: 42-54%
autoimmune-disease-testing-market-portfolio-architecture-1787305918324

High-value Sub-segments and Strategic Watch-out

Novel Biomarker and Companion Diagnostic Testing

Fastest-growing and highest long-term value pool as pharmaceutical partners expand biologic pipelines under accumulating validation evidence and narrowing regulatory approval gaps, though growth remains concentrated in well-resourced partnerships rather than the broader market. Roche Diagnostics and Bio-Rad Laboratories are among those actively expanding capacity today.
Gross Margin: 44-56%

Multiplex Autoantibody Panel Testing

High-value pool growing steadily as laboratories adopt comprehensive panels, particularly across large reference laboratory networks where turnaround efficiency demand has increased meaningfully since 2023 across multiple facility types. Siemens Healthineers and Revvity continue expanding capacity, reinforcing this segment's growth trajectory. Investors increasingly track adoption metrics closely across this competitive segment.
Gross Margin: 38-50%

ANA (Antinuclear Antibody) Testing

Steady volume core segment tied to standard foundational screening workflows, carrying moderate margins below multiplex and companion diagnostic tiers but anchoring most company revenue across the industry consistently each year. Smaller laboratories continue relying on standard ANA testing today. This segment anchors baseline company revenue across the broader industry.
Gross Margin: 20-30%

Conversion-Constrained Regional Laboratory Segment

Strategic watch-out segment facing a persistent adoption ceiling as high capital equipment cost leaves companies dependent on flexible leasing buildout rather than guaranteed broad laboratory conversion nationwide. Companies serving this segment increasingly fund leasing programs to offset this gap. That ceiling persists until leasing investment accelerates industry-wide.
Gross Margin: 16-26%

Recurring Testing Menu Contract Relationship

Autoimmune disease testing purchasing functions closer to a recurring annuity than a single transaction for laboratory relationships, since a testing menu contract typically continues across every subsequent patient sample for the life of the platform relationship rather than any per-test vendor selection decision. Individual patient diagnostic events behave differently, occurring at discrete clinical evaluation points rather than following any predictable purchasing schedule tied to the laborat
Adoption depth varies sharply by end-use vertical. Large reference laboratories and academic medical centers show the deepest engagement with multiplex and companion diagnostic platforms, given dedicated laboratory staff and technical sophistication, while smaller hospital laboratories adopt more slowly since platform investment rarely gets justified by comparatively low individual testing volume. That divide shapes where companies concentrate commercial and validation investment.

A generational shift is underway as younger laboratory directors, trained during the era of routine multiplex panel availability, evaluate platform partners on validated panel accuracy and turnaround efficiency data rather than decades-long familiarity with conventional single-analyte testing workflows alone. That openness gives evidence-forward companies a rare opening to win laboratory share in a category where legacy testing relationships have otherwise been difficult to dislodge.
autoimmune-disease-testing-market-end-use-penetration-index-1787305918812

Where MMA Sees The Opportunity

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / MULTIPLEX VALIDATION INVESTMENT

Expand Panel Validation Before Laboratory Demand Fully Peaks

Laboratories are increasingly requiring validated multiplex panel accuracy before adopting a company as their primary testing partner, and companies without adequate validation investment are losing laboratory relationships to better-equipped competitors as this shift accelerates. Validation investment requires meaningful upfront capital but opens durable laboratory relationships that single-analyte-constrained competitors cannot match once multiplex demand fully materializes. Companies waiting until demand fully peaks will find themselves racing to catch up against incumbents who invested years earlier, a gap that widens each quarter validation investment lags behind competitor programs already underway.
02 / COMPANION DIAGNOSTIC INVESTMENT

Build Pharmaceutical Partnerships Before Pipelines Consolidate

Pharmaceutical developers have not universally committed to a single companion diagnostic partner for autoimmune biologic development, leaving a genuine opportunity for companies willing to fund co-development capability ahead of confirmed industry standardization trends. Waiting for pharmaceutical partnerships to formally consolidate risks missing the commercial differentiation window entirely once a preferred diagnostic partner forms across developer networks. The investment required is meaningful but positions early movers to capture a category growing faster than standalone testing offerings today, a window that will not stay open indefinitely.
03 / REFERENCE LABORATORY PARTNERSHIP DEVELOPMENT

Pursue Network Contracts Before Vendor Consolidation Peaks

Large reference laboratory network testing menu consolidation has repeatedly rewarded early-mover companies first, and companies without dedicated partnership strategies risk ceding this growing category volume to competitors who invest in coordinated relationships earlier. Network partnerships represent a meaningful growth opportunity even though individual hospital laboratory sales currently drive most category revenue. Companies pursuing partnership development now, while competitive density remains manageable, protect volume against the next wave of vendor consolidation reshaping laboratory testing menu decisions, gaining durable advantage as consolidation continues reshaping the category.
04 / REGIONAL ACCESS INVESTMENT

Prioritize South Asia and East Asia Access Investment Now

South Asia and Pacific and East Asia carry rapidly growing diagnosed patient populations relative to their current commercial autoimmune disease testing value, as laboratory infrastructure and diagnostic awareness accelerate across India, China, and neighboring markets. Companies concentrating capacity expansion solely around legacy Western laboratory relationships risk ceding share in the regions where testing volume growth will be steepest through 2036. Early investment in regional manufacturing and distribution partnerships offers a meaningful head start over competitors still anchored entirely to legacy Western customer bases.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Autoimmune Disease Testing Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Autoimmune Disease Testing Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized regional reference laboratory network operating multiple testing facilities across a major United States metropolitan area, processing a large annual volume of rheumatology and autoimmune diagnostic samples. The network reported annual clinical testing revenue of approximately $310 million (client-reported, unverified by MMA) and was evaluating whether to convert its autoimmune testing menu to a multiplex panel platform or continue relying entirely on sequential single-analyte testing instead.
STRATEGIC CHALLENGE
Leadership needed to decide whether adopting a multiplex panel platform, which required capital investment and staff retraining, would generate sufficient turnaround time and cost efficiency benefits to justify the cost relative to continuing existing single-analyte testing workflows. Competing regional laboratory networks were beginning to adopt similar platforms and evaluating vendor options.
MMA APPROACH
MMA benchmarked the client's projected testing volume against comparable reference laboratory networks that had already adopted multiplex panel platforms, modeling turnaround time improvement and cost efficiency against platform investment requirements. The analysis incorporated primary survey data from laboratory directors at ten comparable regional testing networks. Findings were cross-checked against efficiency benchmarks published in recent industry surveys.
KEY FINDINGS
  1. Turnaround time improvement from multiplex adoption exceeded management's initial projections once staff workflow redesign was properly incorporated into the operational planning model used for this analysis.
  2. Peer networks that adopted multiplex panels reported measurably stronger referring physician satisfaction than networks relying entirely on sequential single-analyte testing workflows exclusively.
  3. Platform investment payback occurred faster than initially budgeted once reduced per-test reagent costs were properly incorporated into the financial model used for this specific transition.
  4. Continuing single-analyte-only testing carried a quantifiable competitive risk as referring physicians increasingly viewed faster comprehensive turnaround as a marker of overall laboratory service quality.
CLIENT PROFILE
The client is a mid-sized regional reference laboratory network operating multiple testing facilities across a major United States metropolitan area, processing a large annual volume of rheumatology and autoimmune diagnostic samples. The network reported annual clinical testing revenue of approximately $310 million (client-reported, unverified by MMA) and was evaluating whether to convert its autoimmune testing menu to a multiplex panel platform or continue relying entirely on sequential single-analyte testing instead.
STRATEGIC CHALLENGE
Leadership needed to decide whether adopting a multiplex panel platform, which required capital investment and staff retraining, would generate sufficient turnaround time and cost efficiency benefits to justify the cost relative to continuing existing single-analyte testing workflows. Competing regional laboratory networks were beginning to adopt similar platforms and evaluating vendor options.
MMA APPROACH
MMA benchmarked the client's projected testing volume against comparable reference laboratory networks that had already adopted multiplex panel platforms, modeling turnaround time improvement and cost efficiency against platform investment requirements. The analysis incorporated primary survey data from laboratory directors at ten comparable regional testing networks. Findings were cross-checked against efficiency benchmarks published in recent industry surveys.
KEY FINDINGS
  1. Turnaround time improvement from multiplex adoption exceeded management's initial projections once staff workflow redesign was properly incorporated into the operational planning model used for this analysis.
  2. Peer networks that adopted multiplex panels reported measurably stronger referring physician satisfaction than networks relying entirely on sequential single-analyte testing workflows exclusively.
  3. Platform investment payback occurred faster than initially budgeted once reduced per-test reagent costs were properly incorporated into the financial model used for this specific transition.
  4. Continuing single-analyte-only testing carried a quantifiable competitive risk as referring physicians increasingly viewed faster comprehensive turnaround as a marker of overall laboratory service quality.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 5): Select a multiplex platform partner and begin staff training ahead of formal validation testing across pilot sample types. Phase 2: Phase 2 (Months 6 to 12): Complete clinical validation and launch the platform across full testing volume while tracking turnaround time against the modeled benchmark closely. Phase 3: Phase 3 (Months 13 to 20): Expand panel breadth to additional biomarker categories to capture broader efficiency benefits once initial performance is confirmed.
OUTCOME
Within twelve months of launch, the client reported turnaround time improvement of approximately 42% (client-reported, unverified by MMA), exceeding initial projections meaningfully. Referring physician satisfaction scores improved measurably (client-reported, unverified by MMA), and the network now serves as a regional reference site for smaller autoimmune testing programs.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Autoimmune Disease Testing Market?

The autoimmune disease testing market was valued at approximately $5.40 billion in 2025. Growth is driven primarily by expanding multiplex panel adoption and rising companion diagnostic requirements.

How large will the Autoimmune Disease Testing Market be by 2036?

The market is forecast to reach approximately $13.11 billion by 2036, roughly 2.24 times its 2026 value as multiplex and companion diagnostic formats broaden globally.

What is the CAGR for the Autoimmune Disease Testing Market 2026 to 2036?

The market is forecast to grow at an 8.4% CAGR between 2026 and 2036. Bull and bear scenarios range from roughly 7.1% to 9.6% depending on conversion pace and reimbursement trends.

Which segment is growing fastest?

Novel biomarker and companion diagnostic testing is the fastest-growing segment at approximately 14.8% CAGR, roughly 1.76 times the overall market growth rate. Multiplex autoantibody panel testing follows as the second-fastest segment.

Who are the major companies in the Autoimmune Disease Testing Market?

Leading companies include Roche Diagnostics, Siemens Healthineers, Revvity, Bio-Rad Laboratories, and Werfen, together holding an estimated 44% of global commercial revenue. Smaller specialized developers make up the remaining share.

Which country is growing fastest?

Mexico is the fastest-growing country at approximately 11.2% CAGR, driven by expanding private laboratory infrastructure and rising diagnostic awareness. Germany still commands the largest overall share of commercial value.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Biomarker and Platform Type

  • ANA (Antinuclear Antibody) Testing
  • Rheumatoid Factor and Anti-CCP Testing
  • Celiac Disease Serology Panels
  • Multiplex Autoantibody Panel Testing
  • Thyroid Autoimmune Antibody Testing
  • Novel Biomarker and Companion Diagnostic Testing

By End-Use Testing Setting

  • Hospital Laboratories
  • Reference Laboratories
  • Physician Office Testing
  • Academic Medical Center Laboratories

By Commercial Dimension

  • Laboratory Instrument and Reagent Sales
  • Testing Menu Contract Agreements
  • Companion Diagnostic Partnership Contracts
  • Government and Institutional Procurement

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The autoimmune disease testing market covers in vitro diagnostic assays used to detect autoantibodies and biomarkers associated with autoimmune conditions including rheumatoid arthritis, lupus, celiac disease, and autoimmune thyroid disease. It spans single-analyte enzyme-linked immunosorbent assays, multiplex panel platforms, and companion diagnostic tests sold to hospital laboratories, reference laboratories, and physician office testing settings. Autoimmune disease treatment products, unrelated infectious disease serology testing, and general inflammatory marker panels without autoimmune-specific indication are excluded from this scope.
Quantitative Units
USD billions (current prices); test volume in millions where applicable
Segmentation Dimensions
By Biomarker and Platform Type; By End-Use Testing Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Thailand, Malaysia, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Revvity Inc., Bio-Rad Laboratories Inc., Werfen S.A., Abbott Laboratories, Thermo Fisher Scientific Inc., Grifols S.A., Beckman Coulter Inc., Trinity Biotech plc, QuidelOrtho Corporation, Immunodiagnostic Systems Holdings PLC, ELITechGroup SAS, Aesku.Diagnostics GmbH and Co. KG, MedMira Inc., Svar Life Science AB, Alpha Laboratories Ltd., R-Biopharm AG, Zeus Scientific Inc., Diasorin S.p.A.
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-163
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Autoimmune Disease Testing Market Report (2026 to 2036).

This report analyzes the global autoimmune disease testing market, covering single-analyte, multiplex, and companion diagnostic segments across all seven MMA-tracked global regions. It includes detailed market sizing and forecasts through 2036, competitive benchmarking of the top twenty vendors across large diversified diagnostics companies and specialized immunoassay developers, and segment-level analysis of multiplex adoption. The report draws on MMA's primary survey of 3,800 respondents and 47 expert interviews conducted in the fourth quarter of 2025, supplemented by company disclosures and government health agency data. Buyers receive full access to regional data tables, competitive profiles, and strategic recommendations tailored to developers, laboratory networks, and healthcare investors worldwide.
Full seven-region market sizing and forecast data
Competitive benchmarking of twenty profiled industry vendors
Segment-level analysis of multiplex adoption trends
Primary survey data from 3,800 global respondents
Expert interview insights from 47 immunology diagnostics specialists
Strategic recommendations for developers and laboratory networks

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts